A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Peloton Therapeutics, Inc. was founded in 2011 with the aim of capitalizing on untapped biomedical breakthroughs. By engaging in productive collaborations with world-class scientific visionaries, Peloton has been able to create innovative medicines to address the unmet needs of patients afflicted with life-threatening diseases.
Peloton’s lead investigational therapy, PT2385, is in Phase 1 clinical development as a selective, potent, and orally bioavailable treatment for advanced clear cell renal cell carcinoma (ccRCC). Preclinical data supports the application of PT2385 in other oncology indications such as glioblastoma. In addition to its clinical program, Peloton has a strong discovery pipeline.
Peloton is backed by a strong group of investors and supported by prominent scientific experts and business advisors. The company has recruited more than 25 experienced scientists forming a team with an extensive drug discovery and development track record. Prior to joining Peloton, the leadership team alone collectively advanced more than 20 drugs into clinical trials.
In addition to its internal scientific expertise, Peloton has successfully cultivated relationships with several investigators at leading academic institutions to gain direct access to cutting-edge science. Many of the discoveries leveraged by Peloton are the culmination of years of basic research not available in the public domain, affording the company first-mover advantage in developing innovative drug candidates.
Peloton is committed to the idea that teamwork is critical for maximizing the value of its programs and reaching the broadest patient population who might benefit from those discoveries. Peloton seeks to partner with innovative pharmaceutical and biotechnology companies with a shared vision to create meaningful medical treatment breakthroughs and a commitment to accelerating the development and commercialization of new medicines.